Treatment to target in Type 2 diabetes: successful glycaemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy

被引：0
|
作者：
Riddle, M
Rosenstock, J
机构：
[1] Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA
[2] Dallas Diabet & Endocrine Ctr, Dallas, TX USA
来源：
DIABETOLOGIA | 2002年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
150
引用
收藏
页码：A52 / A52
页数：1
相关论文
共 50 条
  • [41] Sustained glycaemic control and less nocturnal hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml over 1 year in Japanese people with type 1 diabetes mellitus
    Matsuhisa, M.
    Koyama, M.
    Cheng, X.
    Sumi, M.
    Hirose, T.
    DIABETOLOGIA, 2015, 58 : S2 - S3
  • [42] Reduced nocturnal hypoglycaemia with insulin degludec vs insulin glargine: a two year trial in Type 2 diabetes
    Cariou, B.
    Rodbard, H.
    Zinman, B.
    Philis-Tsimikas, A.
    Handlesman, Y.
    Skoth, T. V.
    Chu, P-L
    Mathieu, C.
    DIABETIC MEDICINE, 2013, 30 : 55 - 55
  • [43] Treatment to target study: Timing and frequency of nocturnal hypoglycemia. The value of adding bedtime basal insulin glargine over NPH insulin in insulin-naive patients with Type 2 diabetes on oral agents
    Rosenstock, J
    Riddle, MC
    DIABETES, 2002, 51 : A482 - A482
  • [44] Taspoglutide added to metformin provides comparable glycaemic control as insulin glargine with superior weight loss and less hypoglycaemia in type 2 diabetes: The T-emerge 5 Trial
    Ampudia-Blasco, F. J.
    Nauck, M.
    Andjelkovic, M.
    Horton, E.
    Boldrin, M.
    Balena, R.
    DIABETOLOGIA, 2010, 53
  • [45] Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK
    McEwan, Phil
    Poole, Chris D.
    Tetlow, Tony
    Holmes, Paul
    Currie, Craig J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S7 - S19
  • [46] Nocturnal glucose metabolism after a single bedtime injection of insulin glargine or NPH insulin in patients with type 2 diabetes
    Fischer, Britta
    Soydan, Nedim
    Eckhard, Michael
    Ehl, Julia
    Kunz, Clemenis
    Bretzel, Reinhard G.
    Linn, Thomas
    DIABETES, 2006, 55 : A111 - A111
  • [47] Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients
    Pfeiffer, C
    Winkler, F
    Luger, A
    Pieber, T
    Saudek, F
    Skrha, J
    Hermansen, K
    Lervang, HH
    Nistrup-Holmegaard, S
    Bergkulla, S
    Lembcke, HJ
    Schulze, J
    Petersen, KG
    Haslbeck, M
    Jonker, JJC
    Vaaler, S
    Rolstad, OJ
    Distiller, LA
    Robertson, LI
    Omar, MAK
    Wing, J
    Arner, P
    Arnqvist, H
    Lager, I
    Lennerhagen, P
    Borthwick, LJ
    Hattersley, A
    Owens, DR
    Matthews, DR
    Nattrass, M
    DIABETIC MEDICINE, 2003, 20 (07) : 545 - 551
  • [48] Starting insulin for Type 2 diabetes with insulin glargine added to oral agents versus twice-daily premixed insulin alone
    Janka, HU
    Plewe, G
    Kliebe-Frisch, C
    Schweitzer, MA
    Yki-Järvinen, H
    DIABETOLOGIA, 2004, 47 : A269 - A270
  • [49] PERSISTENCE WITH BASAL SUPPORTED ORAL THERAPY-COMPARISON OF INSULIN GLARGINE VERSUS NPH INSULIN
    Quinzler, R.
    Ude, M.
    Franzmann, A.
    Feldt, S.
    Leuner, K.
    Mueller, W. E.
    Dippel, F. W.
    Schulz, M.
    VALUE IN HEALTH, 2009, 12 (07) : A234 - A234
  • [50] Therapy in type 2 diabetes: Insulin glargine vs. 2 NPH insulin both in combination with glimepiride
    Eliaschewitz, FG
    Calvo, C
    Valbuena, H
    Ruiz, M
    Aschner, P
    Villena, J
    Ramirez, LA
    Jimenez, J
    ARCHIVES OF MEDICAL RESEARCH, 2006, 37 (04) : 495 - 501
12345